{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-025463","form_type":"8-K","ticker":"PBYI","cik":"0001401667","company_name":"PUMA BIOTECHNOLOGY, INC.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.895642+00:00","generated_at":"2026-05-17T17:18:21.708405+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Puma Biotechnology Q2 net income $5.9M vs year-ago loss; revenue rises to $52.4M","bullets":["GAAP EPS $0.12 vs $(0.09) loss; adjusted EPS $0.15 vs $(0.05) loss.","Net product revenue $49.2M (+11% YoY); total revenue $52.4M (+11% YoY).","Q3 2025 guidance: net product revenue $46–48M, total revenue $48–51M, net income $2–4M.","Full-year 2025 revenue outlook reaffirmed at $212–222M; gross-to-net adjustment raised to 21.5–22.0%.","Cash & equivalents $96M; key milestones: alisertib interim data in Q4 2025 for two Phase II trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-025463","json":"https://secwatch.observer/filing/0001437749-25-025463.json","markdown":"https://secwatch.observer/filing/0001437749-25-025463.md","text":"https://secwatch.observer/filing/0001437749-25-025463.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401667/000143774925025463/0001437749-25-025463-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401667/000143774925025463/pbyi20250724_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:18:21.708405+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}